**Artoxan (Injections / Capsules)**

(\textit{Tenoxicam})

\textbf{CONTENT:}
Capsules. Capsule contains tenoxicam 20 mg.
Vials. Vial contains active ingredient: tenoxicam 20 mg.

\textbf{PHARMACOLOGICAL PROPERTIES:}
\textbf{PHARMACODYNAMICS.} Artoxan is effective non-steroid anti-inflammatory drug (\textit{NSAID}) with intense anti-inflammatory, analgetic and less expressed antipyretic action.
Properties of the preparation are de-termined by inhibition of both cyclooxygenase enzyme isoforms that leads to decrease in metabolism of the arachidonic acid and blockade of prostaglandin synthesis.
The anti-inflammatory effect is determined by reduction of capillaries permeability (limits exudation), stabilization of lysosomal membranes (prevents the exit of lysosomes enzymes, causing tissue damage), suppression of synthesis or inactivation of inflammation mediators (prostaglandins, histamine, bradykinin, lymphokins, comlement factors). It reduces the quantity of free radicals in the center of inflammation, supresses chemotaxis and phagocytosis. Inhibits the proliferative phase of inflammation, reduces postinflammatory sclerosis of tissues; renders chondroprotective action. The preparation reduces painful sensitivity in the center of inflammation and has the effect on thalamic centers of pain, possesses desensitizing action (at long application). At rheumatic diseases weakens the pain in joints at rest and at movement, reduces morning constraint and swelling of joints, improves functions and increases volume of movements of joints.

\textbf{PHARMACOKINETICS.} After oral intake of capsules of Artoxan absorbtion is fast and complete. Pick concentration will develop in 2 hours. Intake after the meal decreases absorbtion. Bioavailability close to 100%. Has a long period of half-life 60-75 h. It easily passes through the histohematogenous barriers, well penetrates to the synovial fluid.
The preparation is characterized by high bioavailability - close to 100 %.

\textbf{THERAPEUTIC INDICATIONS:}
Inflammatory-degenerative diseases of the musculoskeletal system, accompanied by pain syndrome:
- rheumatoid arthritis, gout arthritis, ankylosing spondylitis (Bekhterev's disease);
- infectious nonspecific polyarthritis;
- osteoarthritis, osteochondrosis;
- tendinitis, bursitis, myositis, periarthritis;
- arthralgia, neuralgia, myalgia, ishalgia, lumbago;
- traumas, burns.

\textbf{CONTRAINDICATIONS:}
- Hypersensitivity to tenoxicam or nother NSAID;
- Erosive or ulcerative lesions of GIT;
- Gastroenteric bleedings.
SIDE EFFECTS:
From digestive system: pains and unpleasant feelings in stomach, nausea, flatulence. From nervous system: dizziness, headache. Allergic reactions: itch, urticaria, erythema, syndromes of Stevens-Johnson's and Lyell's. Laboratory parameters: increase of creatinine and urea concentration in plasma, increase of "hepatic" transaminases activity.

DOSAGE AND ADMINISTRATION:
Intended for intramuscular or intravenous injection, oral intake. Prescribed in the dose of 20 mg once a day, maintenance dose - 10 mg a day. In very strong pain syndrome it is possible to increase the dose up to 40 mg once a day. At acute attacks of gout arthritis: 20 mg 2 times a day within the first 2-3 days, then 20 mg once a day within 5 days.

PACKAGING:
3 vials with lyophilized powder and 3 ampoules with solvent in contour tray. 1 contour tray in carton box with enclosed leaflet. 10 capsules in blister. One blister with leaflet in carton box.